Rehovot, Israel

Peptor Limited


USPTO Granted Patents = 14

% Expired Patents = 7.1

Forward Citations = 206

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Vered Hornik (7 out of 8 patents)

silverMedal Chaim Gilon (6 out of 27 patents)

bronzeMedal Alon Seri-Levy (5 out of 14 patents)

4.  Doron Eren (4 out of 12 patents)

5.  Irina Zeltser (4 out of 6 patents)

6.  Gal Bitan (4 out of 5 patents)

7.  Dan Muller (4 out of 6 patents)

8.  Gary Gellerman (4 out of 5 patents)

9.  Yoseph Salitra (1 out of 9 patents)

10.  Tamar Yechezkel (1 out of 6 patents)

11.  Michel M Afargan (1 out of 2 patents)

12.  Eliezer Falb (1 out of 2 patents)

13.  Eran Hadas (1 out of 3 patents)

14.  Mich El M Afargan (1 out of 1 patent)

15.  Rakefet Rosenfeld (1 out of 1 patent)


14 patents:

Company Overview
Peptor Limited is a biotechnology company based in Rehovot, Israel, specializing in the development of innovative peptide-based therapeutics. The organization focuses on harnessing the unique properties of peptides to create treatments for various medical conditions, particularly in the fields of oncology and metabolic disorders. With a commitment to advancing healthcare solutions, Peptor Limited leverages cutting-edge research and technology to address unmet medical needs and improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

14 Patents

#32 in Rehovot

#463 in Israel

#42,290 in the World

Rehovot, IL
Rehovot, Israel
Forward Citations = 206

21 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Peptor Limited. Retrieved from https://idiyas.com/company/peptor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…